Bellerophon Therapeutics is a biotechnology business based in the US. Bellerophon Therapeutics shares (BLPH) are listed on the PINK and all prices are listed in US Dollars. Its last market close was $0.06 – an increase of 48.65% over the previous week. Bellerophon Therapeutics employs 18 staff and has a trailing 12-month revenue of around $5.6 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.06 |
|---|---|
| 52-week range | $0.03 - $0.08 |
| 50-day moving average | $0.04 |
| 200-day moving average | $0.05 |
| Wall St. target price | $2.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.89 |
Historical closes compared with the close of $0.055 from 2024-11-22
| 1 week (2024-11-15) | 48.65% |
|---|---|
| 1 month (2024-10-24) | 52.78% |
| 3 months (2024-08-23) | 57.14% |
| 6 months (2024-05-23) | -2.31% |
| 1 year (2023-11-22) | 66.67% |
|---|---|
| 2 years (2022-11-23) | -94.61% |
| 3 years (2021-11-23) | 3.37 |
| 5 years (2019-11-21) | 5.4675 |
| Revenue TTM | $5.6 million |
|---|---|
| Gross profit TTM | $0 |
| Return on assets TTM | -78.47% |
| Return on equity TTM | -165.96% |
| Profit margin | -164.06% |
| Book value | $0.30 |
| Market Capitalization | $672,798 |
TTM: trailing 12 months
We're not expecting Bellerophon Therapeutics to pay a dividend over the next 12 months.
Bellerophon Therapeutics's shares were split on a 1:15 basis on 9 February 2020 . So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Bellerophon Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Bellerophon Therapeutics shares which in turn could have impacted Bellerophon Therapeutics's share price.
Over the last 12 months, Bellerophon Therapeutics's shares have ranged in value from as little as $0.03 up to $0.0785. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Bellerophon Therapeutics's is 0.704. This would suggest that Bellerophon Therapeutics's shares are less volatile than average (for this exchange).
Bellerophon Therapeutics, Inc. , a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.